Literature DB >> 18398914

Geographical variation of medicated parkinsonism in Finland during 1995 to 2000.

Aki S Havulinna1,2, Pentti J Tienari3, Reijo J Marttila4, Kirsti K Martikainen5, Johan G Eriksson1,6, Olli Taskinen1, Elena Moltchanova1, Marjatta Karvonen1.   

Abstract

We performed a nation-wide study on geographical variation in the incidence and prevalence of medicated parkinsonism among the Finns aged > or =30 years using Bayesian spatial conditional autoregressive models. Registry of reimbursed medication for parkinsonism and a prescription database of purchase of these drugs were used to identify the study subjects. They were located by the map coordinates of the place of residence and aggregated into regular 100 km(2) grid cells. A total of 7,190 incident and 10,616 prevalent cases were found. The age-adjusted annual incidence was 32.6/100,000 (95% HDR 31.8-33.4) during the years 1995 to 2000 and prevalence was 268/100,000 (95% HDR 263-274) in 2000. The male to female ratio was 1.45 (95% HDR 1.39-1.51) in incidence and 1.54 (95% HDR 1.47-1.61) in prevalence. There was strong evidence for geographic variation in incidence and prevalence. A zone with high incidence and prevalence was identified in the eastern and central part of Finland. There was no evidence for difference in incidence and prevalence between urban and rural areas. The marked (more than two-fold) geographic variation can hardly be caused solely by practices of the registration and collection of data on diagnosis or by methodological issues, but rather suggests to geographic variation in protective and predisposing factors of Parkinsonism in Finland.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398914     DOI: 10.1002/mds.22024

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  3 in total

1.  POLG1 polyglutamine tract variants associated with Parkinson's disease.

Authors:  Johanna Eerola; Petri T Luoma; Terhi Peuralinna; Sonja Scholz; Coro Paisan-Ruiz; Anu Suomalainen; Andrew B Singleton; Pentti J Tienari
Journal:  Neurosci Lett       Date:  2010-04-24       Impact factor: 3.046

2.  Clinical features of Parkinson's disease patients are associated with therapeutic misconception and willingness to participate in clinical trials.

Authors:  Emmi Reijula; Anna-Maija Pietilä; Arja Halkoaho; Tuomas Selander; Kirsti Martikainen; Reetta Kälviäinen; Tapani Keränen
Journal:  Trials       Date:  2017-09-29       Impact factor: 2.279

3.  Biallelic expansion in RFC1 as a rare cause of Parkinson's disease.

Authors:  Laura Kytövuori; Jussi Sipilä; Hiroshi Doi; Anri Hurme-Niiranen; Ari Siitonen; Eriko Koshimizu; Satoko Miyatake; Naomichi Matsumoto; Fumiaki Tanaka; Kari Majamaa
Journal:  NPJ Parkinsons Dis       Date:  2022-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.